---
document_datetime: 2025-11-23 08:01:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vanflyta-0.html
document_name: vanflyta-0.html
version: success
processing_time: 0.0665854
conversion_datetime: 2025-12-28 14:35:10.462905
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vanflyta

[RSS](/en/individual-human-medicine.xml/67249)

##### Refused

This medicine has been refused authorisation

quizartinib

Medicine

Human

Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vanflyta](#news-on)
- [More information on Vanflyta](#more-information-on-vanflyta-65343)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The European Medicines Agency has recommended the refusal of the marketing authorisation for Vanflyta, a medicine intended for the treatment of adults with acute myeloid leukaemia (AML) (a cancer of the white blood cells).

The Agency issued its opinion on 17 October 2019. The company that applied for authorisation, Daiichi Sankyo Europe GmbH, may ask for re-examination of the opinion within 15 days of receiving the opinion.

Expand section

Collapse section

## What is Vanflyta and what was it intended to be used for?

Vanflyta was developed as a cancer medicine for the treatment of a type of AML called 'FLT3-ITD positive' (when the cancer cells have a certain change in the gene for a protein called FLT3). Vanflyta was to be used in adult patients whose disease had come back or did not respond to previous treatments and for continuation of treatment after the patient had undergone a haematopoietic stem cell transplant (HSCT, a transplant of cells that can develop into different types of blood cells).

Vanflyta contains the active substance quizartinib and was to be available as tablets.

Vanflyta was designated an 'orphan medicine' (a medicine used in rare diseases) on 23 March 2009 for the treatment of AML. Further information on the [orphan designation can be found on the Agency's website](http://ema.europa.eu/medicines/human/orphan-designations/eu309622) .

## How does Vanflyta work?

The active substance in Vanflyta, quizartinib, is a 'receptor tyrosine kinase inhibitor'. It works by blocking FLT3, a protein involved in cell growth and proliferation. By blocking FLT3, quizartinib is expected to stop cancer cells from multiplying and thus slow down the progression of the disease.

## What did the company present to support its application?

The company presented the results of a study in 367 patients with FLT3-ITD positive AML whose disease did not respond to treatment or came back after treatment. Vanflyta was compared with other cancer medicines and the main measure of effectiveness was overall survival (how long patients lived) after being given Vanflyta or the comparator medicines.

## What were the main reasons for refusing the marketing authorisation?

Although the results from the main study indicated a marginal improvement in overall survival for patients given Vanflyta, the study had important limitations which meant that the effectiveness of Vanflyta could not be sufficiently demonstrated.

Therefore, the Agency's opinion was that the benefits of Vanflyta did not outweigh its risks and it recommended refusing marketing authorisation.

## Does this refusal affect patients in clinical trials or compassionate use programmes?

The company informed the Agency that there are no consequences for patients in clinical trials or in compassionate use programmes with Vanflyta.

If you are in a clinical trial or compassionate use programme and need more information about your treatment, speak with your clinical trial doctor.

Questions and answers on the refusal of the marketing authorisation for Vanflyta (quizartinib)

Adopted

Reference Number: EMA/559309/2019

English (EN) (72.47 KB - PDF)

**First published:** 18/10/2019

**Last updated:** 06/01/2020

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_en.pdf)

[Other languages (22)](#file-language-dropdown-739)

български (BG) (124.88 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_bg.pdf)

español (ES) (100.56 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_es.pdf)

čeština (CS) (121.05 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_cs.pdf)

dansk (DA) (100.73 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_da.pdf)

Deutsch (DE) (104.13 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_de.pdf)

eesti keel (ET) (98.97 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_et.pdf)

ελληνικά (EL) (126.4 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_el.pdf)

français (FR) (102.05 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_fr.pdf)

hrvatski (HR) (120.55 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_hr.pdf)

italiano (IT) (99.65 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_it.pdf)

latviešu valoda (LV) (119.77 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_lv.pdf)

lietuvių kalba (LT) (123.61 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_lt.pdf)

magyar (HU) (121.16 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_hu.pdf)

Malti (MT) (123.46 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_mt.pdf)

Nederlands (NL) (100.48 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_nl.pdf)

polski (PL) (121.6 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_pl.pdf)

português (PT) (101.98 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_pt.pdf)

română (RO) (120.7 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_ro.pdf)

slovenčina (SK) (122.04 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sk.pdf)

slovenščina (SL) (120.56 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sl.pdf)

Suomi (FI) (98.36 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_fi.pdf)

svenska (SV) (110.2 KB - PDF)

**First published:**

18/10/2019

**Last updated:**

06/01/2020

[View](/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sv.pdf)

## Product details

Name of medicine Vanflyta Active substance quizartinib dihydrochloride International non-proprietary name (INN) or common name quizartinib Therapeutic area (MeSH) Leukemia, Myeloid, Acute Anatomical therapeutic chemical (ATC) code L01XE

### Pharmacotherapeutic group

Antineoplastic agents

## Application details

EMA product number EMEA/H/C/004468 Marketing authorisation applicant Daiichi Sankyo Europe GmbH Opinion adopted 17/10/2019 Refusal of marketing authorisation 19/12/2019

## Assessment history

Vanflyta : EPAR - Refusal public assessment report

Adopted

Reference Number: EMA/CHMP/602286/2019

English (EN) (5.4 MB - PDF)

**First published:** 06/01/2020

[View](/en/documents/assessment-report/vanflyta-epar-refusal-public-assessment-report_en.pdf)

#### News on Vanflyta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019) 18/10/2019

#### More information on Vanflyta

The European Commission initially refused the marketing authorisation for this medicine. Following a later application by the company, the CHMP issued a [positive opinion](https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vanflyta_en.pdf) recommending that the the marketing authorisation be granted.

**This page was last updated on** 06/01/2020

## Share this page

[Back to top](#main-content)